The Fas system is not significantly involved in apoptosis in human hepatocellular carcinoma

Liver

Volumn 18, Issue 2, 1998, Pages 117-123

  Kubo, Keiko ^a   Matsuzaki, Yuko ^a   Okazaki, Muneko ^a   Kato, Akira ^a   Kobayashi, Nobuyuki ^b   Okita, Kiwamu ^a  

^a YAMAGUCHI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b NAGASAKI UNIVERSITY   (Japan)

Author keywords

Apoptosis; Fas; Fas ligand; Hepatocellular carcinoma; In situ DNA nick end labeling

Indexed keywords

DNA FRAGMENT; FAS ANTIGEN; FAS LIGAND; KI 67 ANTIGEN; LIVER PROTEIN;

ADULT; AGED; APOPTOSIS; ARTICLE; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LABORATORY TEST; LIVER CELL CARCINOMA; MALE; PATHOGENESIS; PROTEIN EXPRESSION;

EID: 0031967249     PISSN: 01069543     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0676.1998.tb00136.x     Document Type: Article

References (30)

1. CARSON D A, RIBEIRO J M. Apoptosis and disease. Lancet 1993; 341: 1251-4.
2. WILLLAMS G T. Programmed cell death: apoptosis and oncogenesis. Cell 1991; 65: 1097-8.
3. THOMPSON C B. Apoptosis in the pathogenesis and treatment of disease. Science 1995; 267: 1456-62.
4. QUE F G, GORES G J. Cell death by apoptosis: basic concepts and disease relevance for gastroenterologist. Gastroenterology 1996, 110: 1238-43.
5. KERR J F R, WINTERFORD C M, HARMON B V. Apoptosis: its significance in cancer and cancer therapy. Cancer 1994; 73: 2013-26
6. FUKUDA K, KOJIRO M, CHIU J-F. Demonstration of extensive chromatin cleavage in transplanted Morris hepatoma 7777 tissue: apoptosis or necrosis? Am J Pathol 1993; 142: 935-46.
7. BURSH W TAPER H S, LAUER B, SCHULTE-HERMANN R. Quantitative histological and histochemical studies on the occurrence and stages of controlled cell death (apoptosis) during regression of rat liver hyperplasia. Virchows Arch (Cell Pathol) 1985; 50: 153-66.
8. COLUMBANO A, LEDDA-COLUMBANO G M, RAJALAKSHMI S, SARMA D S R. Occurrence of cell death (apoptosis) in preneoplastic and neoplastic liver cells: a sequential study. Am J Pathol 1984; 116: 441-6.
9. BURSCH W, LAUER B, TIMMERMANN-TROSIENER I, BARTHEL G, SCHUPPIER J, SCHULTE-HERMANN R. Controlled death (apoptosis) of normal and putative preneoplastic cells in rat liver following withdrawal of tumor promoters. Carcinogenesis 1984; 5: 453-8.
10. GRASL-KRAUPP B, RUTTKAY-NEDECKY B, MÜLLAUER L, et al. Inherent increase of apoptosis m liver tumors: implications for carcinogenesis and tumor regression. Hepatology 1997; 25: 906-12.
11. HINO N, HIGASHI T, NOUSO K, NAKATSUKASA H, TSUJI T. Apoptosis and proliferation of human hepatocellular carcinoma. Liver 1996; 16: 123-9.
12. y and p53) in human cholangiocarcinomas and hepatocellular carcinomas. Pathol Int 1996; 46: 764-70.
13. FELDMANN G. Liver apoptosis. J Hepatol 1997; 26: 1-11.
14. STRAND S, HOFMANN W J, HUG H, et al. Lymphocyte apoptosis induced by CD95 (APO-1/Fas) ligand-expressing tumor cells - a mechanism of immune evasion? Nature Med 1996; 2: 1361-6.
15. Liver Cancer Study Group of Japan. The general rule of the clinical and pathological study of primary liver cancer, 3rd edn. Tokyo: Kanahara Press, 1992.
16. HERMAEC P, SOBIN L H. UICC TNM classification of malignant tumors, 3rd edn., 2nd rev. Berlin: Springer-Verlag, 1992: 104-11.
17. GAVRIELI Y, SHERMAN Y, BEN-SASSON S A. Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J Cell Biol 1992; 119: 493-501.
18. GRASL-KRAUPP B, RUTTKAY-NEDECKY B, KOUDELKA H, BUKOWSKA K, BURSCH W, SCHULTE-HERMANN R. In situ detection of fragmented DNA (TUNEL assay) fails to discriminate among apoptosis, necrosis, and autolytic cell death: a cautionary note. Hepatology 1995; 21: 1465-8.
19. KOJI T, KOBAYASHI N, NAKANISHI Y, et al. Immunohistochemical localization of Fas antigen in paraffin sections with rabbit antibodies against human synthetic Fas peptides. Acta Histochem Cytochem 1994; 27: 459-63.
20. OKAZAKI M, HINO K, FUJII K, et al. Immunohistochemistry study of Fas antigen in liver patients with chronic hepatitis and autoimmune liver disease. Int Hepatol Commun 1995; 3: 285-9.
21. OKAZAKI M, HINO K, FUJII K, KOBAYASHI N, OKITA K. Hepatic Fas antigen expression before and after interferon therapy in patients with chronic hepatitis C. Dis Dis Sci 1996; 41: 2453-8.
22. HAKUNO N, KOJI T, YANO T, et al. Fas/APO-1/CD95 system as a mediator of granulosa cell apoptosis in ovarian follicle atresia. Endocrinology 1996; 137: 1938-48.
23. HOLLOWOOD K, MACARTNEY J C. Reduced apoptotic cell death in follicular lymphoma. J Pathol 1991; 163: 337-42.
24. ISHIDA M, GOMYO Y, TATEBE S, OHFUJI S, ITO H. Apoptosis in human gastric mucosa, chronic gastritis, dysplasia and carcinoma: analysis by terminal deoxynucleotidyl transferase-mediated dUTP-biotin nick end labeling. Virchows Arch 1996; 428: 229-35.
25. KASAGI N, GOMYO Y, SHIRAI H, TSUJITANI S, ITO H. Apoptotic cell death in human gastric carcinoma: analysis by terminal deoxynucleotidyl transferase-mediated dUTP-biotin nick end labeling. Jpn J Cancer Res 1994; 85: 939-45.
26. LEITHHÄUSER F, DHEIN J, MECHTERSHEIMER G, et al. Constitutive and induced expression of APO-1, a new member of the nerve growth factor/tumor necrosis factor receptor superfamily, in normal and neoplastic cells. Lab Invest 1993; 69: 415-29.
27. NAGATA S, GOLSTEIN P. The Fas death factor. Science 1995; 267: 1449-56.
28. MITA E, HAYASHI N, ITO S, et al. Role of Fas ligand in apoptosis induced by hepatitis C virus infection. Biochem Biophys Res Commun 1994; 204: 468-74.
29. GALLE P R, HOFMANN W J, WALCZAK H, et al. Involvement of the CD95 (APO-1/Fas) receptor and ligand in liver damage. J Exp Med 1995; 182: 1223-30.
30. OWEN-SCHAUB L B, RADINSKY R, KRUZEL E, BERRY K, YONEHARA S. Anti-Fas on nonhematopoietic tumors: levels of Fas/APO-1 and bcl-2 are not predictive of biological responsiveness. Cancer Res 1994; 54: 1580-6.